PROTAC KRASG12C Degrader-LC-2
|
|
- CAS号:
- 2502156-03-6
- 英文名:
- PROTAC KRASG12C Degrader-LC-2
- 英文别名:
- LC-2;PROTAC KRASG12C Degrader-LC-2;(2S,4R)-1-((S)-2-(3-(3-((S)-2-(((7-(8-Chloronaphthalen-1-yl)-4-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)propoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-m;(2S,4R)-1-((S)-2-(3-(3-((S)-2-(((7-(8-Chloronaphthalen-1-yl)-4-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)propoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
- 中文名:
- PROTAC KRASG12C Degrader-LC-2
- 中文别名:
- LC 2|||PROTAC KRASG12C DEGRADER-LC-2|||LC2;(2S,4R)-1-((S)-2-(3-(3-((S)-2-(((7-(8-氯萘-1-基)-4-((S)-3-(氰基甲基)-4-(2-氟丙烯酰基)哌嗪-1-基)-5,6,7,8-四氢吡啶并[3,4-D]嘧啶-2-基)氧基)甲基)吡咯烷-1- 基)丙氧基)丙酰胺基)-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺
- CBNumber:
- CB78200421
- 分子式:
- C59H71ClFN11O7S
- 分子量:
- 1132.78
- MOL File:
- Mol file
|
|
|
PROTAC KRASG12C Degrader-LC-2化学性质
-
密度:
-
1.297±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO: 50 mg/mL (44.14 mM; ultrasonic and warming and heat to 80°C)
-
|
-
形态:
-
Solid
-
|
-
酸度系数(pKa):
-
14.07±0.40(Predicted)
-
|
-
颜色:
-
Off-white to brown
-
|
PROTAC KRASG12C Degrader-LC-2性质、用途与生产工艺
LC-2 是首创的内源性 KRAS G12C 的 PROTAC 降解剂,DC50 在 0.25 和 0.76 μM 之间。LC-2 是一种 PROTAC,与 MRTX849 共价结合 KRAS G12C 并招募 E3 连接酶 VHL,诱导 KRAS G12C 快速持续降解,导致纯合和杂合子 KRAS G12C 细胞系 MAPK 信号的抑制。
KRAS(G12C)
0.25-0.76 μM (DC
50
)
|
VHL
|
LC-2 induces degradation of endogenous KRASG12C in multiple KRAS mutant cancer cell (NCI-H2030, MIA PaCa-2, SW1573, NCI-H23 and NCI-H358 cells) with DC
50
s between 0.25 and 0.76 μM. LC-2-induced KRASG12C degradation occurs via a
bona fide
PROTAC mechanism. MIA PaCa-2, NCI-H23, and SW1573 cells are treated with 2.5 μM of LC-2 for 6, 24, 48, and 72 h. In all three cell lines, maximal KRAS degradation occurred within 24 h and was sustained up to 72 h.
LC-2-induced (2.5 μM; 6-24 hours) KRAS G12C degradation modulates Erk signaling in homozygous and heterozygous KRAS mutant cell lines.
Western Blot Analysis
Cell Line:
|
MIA PaCa-2 cells and NCI-H23 cells
|
Concentration:
|
2.5 μM
|
Incubation Time:
|
6-24 hours
|
Result:
|
Inhibition and degradation of KRAS G12C decreases pErk signaling at 6 and 24 h in homozygous MIA PaCa-2 cells
|
PROTAC KRASG12C Degrader-LC-2
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2024/04/30 | HY-137516 | (2S,4R)-1-((S)-2-(3-(3-((S)-2-(((7-(8-氯萘-1-基)-4-((S)-3-(氰基甲基)-4-(2-氟丙烯酰基)哌嗪-1-基)-5,6,7,8-四氢吡啶并[3,4-D]嘧啶-2-基)氧基)甲基)吡咯烷-1- 基)丙氧基)丙酰胺基)-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺 LC-2 | 2502156-03-6 | 1mg | 3200元 |
2024/04/30 | HY-137516 | (2S,4R)-1-((S)-2-(3-(3-((S)-2-(((7-(8-氯萘-1-基)-4-((S)-3-(氰基甲基)-4-(2-氟丙烯酰基)哌嗪-1-基)-5,6,7,8-四氢吡啶并[3,4-D]嘧啶-2-基)氧基)甲基)吡咯烷-1- 基)丙氧基)丙酰胺基)-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺 LC-2 | 2502156-03-6 | 5mg | 9800元 |
PROTAC KRASG12C Degrader-LC-2
生产厂家
2502156-03-6, PROTAC KRASG12C Degrader-LC-2 相关搜索:
- LC 2|||PROTAC KRASG12C DEGRADER-LC-2|||LC2
- (2S,4R)-1-((S)-2-(3-(3-((S)-2-(((7-(8-氯萘-1-基)-4-((S)-3-(氰基甲基)-4-(2-氟丙烯酰基)哌嗪-1-基)-5,6,7,8-四氢吡啶并[3,4-D]嘧啶-2-基)氧基)甲基)吡咯烷-1- 基)丙氧基)丙酰胺基)-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺
- 2502156-03-6
- (2S,4R)-1-((S)-2-(3-(3-((S)-2-(((7-(8-Chloronaphthalen-1-yl)-4-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)propoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-m
- (2S,4R)-1-((S)-2-(3-(3-((S)-2-(((7-(8-Chloronaphthalen-1-yl)-4-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)propoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
- LC-2
- PROTAC KRASG12C Degrader-LC-2